September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
2 citations
,
January 2018 in “International journal of research in dermatology” Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
April 2019 in “Journal of Investigative Dermatology” The humanized AA mouse model is better for testing new alopecia areata treatments.
8 citations
,
December 2018 in “Journal of Dermatological Treatment” The PRP-like cosmetic with biomimetic peptides is potentially effective and safe for treating alopecia areata.
3 citations
,
June 2023 in “Journal of cosmetic dermatology” A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
December 2023 in “Portuguese journal of dermatology and venereology” Trichoscopy can reliably distinguish between alopecia areata and trichotillomania.
1 citations
,
September 2023 in “Clinical, cosmetic and investigational dermatology” Certain genetic variants linked to immune response increase the risk of alopecia areata in Taiwanese people.
Liquid nitrogen cryotherapy worked well for many patients with stubborn alopecia areata.
April 2022 in “Journal of evolution of medical and dental sciences” Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” The summit aimed to speed up finding treatments for alopecia areata.
7 citations
,
July 2020 in “Immunological Investigations” The rs231775 genetic variant is linked to a higher risk and severity of Alopecia Areata in males.
April 2024 in “Skin research and technology” Minoxidil with triamcinolone acetonide is more effective for mild alopecia areata when injected with microneedles than when applied topically.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.
April 2023 in “Journal of Investigative Dermatology” Patients and doctors often disagree on alopecia areata severity and treatment satisfaction.
July 2018 in “British Journal of Dermatology” Hair regrowth was seen in 83% of children with alopecia, immune system plays a role in the condition, and various treatments showed effectiveness for hair and nail disorders.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
September 2023 in “Journal of The American Academy of Dermatology” Clinical trials for hair loss in the USA show differences in participation among different races and ethnic groups.
January 2026 in “Dove Medical Press (Taylor and Francis Group)” Strainful life events may significantly trigger alopecia areata.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
6 citations
,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
May 2025 in “JEADV Clinical Practice” Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
40 citations
,
September 2014 in “Journal of cosmetic and laser therapy” Transepidermal drug delivery effectively treated areata alopecia with minimal side effects.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Traditional treatment for pediatric alopecia areata is most effective and should be first choice.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
July 2023 in “Deleted Journal” Alopecia areata is the most common type of baldness treated with corticosteroids and minoxidil.